What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.

Clinical lymphoma & myeloma

Volumn 9 Suppl 3, Issue , 2009, Pages

  Smith, B Douglas ^a   Karp, Judith E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE DISEASE; CLINICAL TRIAL; DRUG THERAPY; HUMAN; LEUKEMIA; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; ONCOLOGY; PATHOLOGY; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG THERAPY; HUMANS; LEUKEMIA; MEDICAL ONCOLOGY; NEOPLASM, RESIDUAL; RESEARCH DESIGN; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 74049092362     PISSN: None     EISSN: 19380712     Source Type: Journal    
DOI: 10.3816/clm.2009.s.027     Document Type: Review

References (63)